Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acut… Read more
Tetra Bio-Pharma Inc. (TBPMQ) - Total Assets
Latest total assets as of August 2022: $3.02 Million USD
Based on the latest financial reports, Tetra Bio-Pharma Inc. (TBPMQ) holds total assets worth $3.02 Million USD as of August 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tetra Bio-Pharma Inc. - Total Assets Trend (2019–2021)
This chart illustrates how Tetra Bio-Pharma Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tetra Bio-Pharma Inc. - Asset Composition Analysis
Current Asset Composition (November 2021)
Tetra Bio-Pharma Inc.'s total assets of $3.02 Million consist of 78.8% current assets and 21.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.7% |
| Accounts Receivable | $255.71K | 3.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $692.25K | 9.2% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2021)
This chart illustrates how Tetra Bio-Pharma Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tetra Bio-Pharma Inc.'s current assets represent 78.8% of total assets in 2021, an increase from 18.9% in 2019.
- Cash Position: Cash and equivalents constituted 64.7% of total assets in 2021, up from 7.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 80.0% in 2019.
- Asset Diversification: The largest asset category is property, plant & equipment at 9.2% of total assets.
Tetra Bio-Pharma Inc. Competitors by Total Assets
Key competitors of Tetra Bio-Pharma Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Tetra Bio-Pharma Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tetra Bio-Pharma Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tetra Bio-Pharma Inc. is currently not profitable relative to its asset base.
Tetra Bio-Pharma Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.25 | 0.81 | 0.81 |
| Quick Ratio | 0.25 | 0.81 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.68 Million | $ -1.35 Million | $ -1.35 Million |
Tetra Bio-Pharma Inc. - Advanced Valuation Insights
This section examines the relationship between Tetra Bio-Pharma Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 48.20 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -74.3% |
| Total Assets | $7.55 Million |
| Market Capitalization | $83.75K USD |
Valuation Analysis
Below Book Valuation: The market values Tetra Bio-Pharma Inc.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tetra Bio-Pharma Inc.'s assets decreased by 74.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tetra Bio-Pharma Inc. (2019–2021)
The table below shows the annual total assets of Tetra Bio-Pharma Inc. from 2019 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-11-30 | $7.55 Million | -74.26% |
| 2020-11-30 | $29.34 Million | +2.70% |
| 2019-11-30 | $28.57 Million | -- |